1999
From: Immunex Corporation
ENBREL Phase III Data Published In Annals Of Internal MedicinePivitol Study of ENBREL in Rheumatoid Arthritis Patients Established Foundation for FDA Approval Who: Immunex Corporation (NSQD:IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), announce the publication of Phase III data for ENBREL (etanercept) for the treatment of rheumatoid arthritis (RA) in the Annals of Internal Medicine. What: The six month study is based on 234 patients with active rheumatoid arthritis with inadequate response to DMARDs. Date of Publication: March 16, 1999 Spokespeople: Study investigators, company spokespersons and patients on ENBREL are available for interviews Contact:
Shari Beagelman 212-614-4673; [email protected]
Nicole Preiss 212-614-5237; [email protected] Background: ENBREL was approved November 2, 1998 by the U.S. Food and Drug Administration as a treatment for moderately to severely active RA in patients who have an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs).
|